Payment overview · 2025
General Payments
$639.53
28 reported records · 12 companies
Healthcare provider profile · identity verified
Htay Win, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FREMONT, CA · NPI 1881642155
Verified facts
What the public records show
CMS Open Payments records show Htay Win, M.D. received $639.53 in general payments during 2025 across 28 reported records.
Kowa Pharmaceuticals America, Inc. accounted for 20.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $129.76 | 20.3% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $100.69 | 15.7% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $81.28 | 12.7% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $56.78 | 8.9% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $50.76 | 7.9% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $50.29 | 7.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.87 | 7.5% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.38 | 5.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.13 | 4.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.98 | 3.9% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.29 | 2.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.32 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $639.53 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $129.76 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $100.69 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $81.28 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $56.78 | 2 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $50.76 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $32.38 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.13 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $29.03 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $28.10 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 76 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
68 | 22 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1116 | 254 |
| Furosemide | Furosemide | 874 | 172 |
| Amlodipine Besylate | Amlodipine Besylate | 825 | 205 |
| Levothyroxine Sodium | Levothyroxine Sodium | 810 | 127 |
| Losartan Potassium | Losartan Potassium | 698 | 178 |
| Metformin Hcl | Metformin Hcl | 617 | 161 |
| Gabapentin | Gabapentin | 517 | 132 |
| Eliquis | Apixaban | 500 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 476 | 122 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 438 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 409 | 96 |
| Omeprazole | Omeprazole | 381 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 354 | 110 |
| Simvastatin | Simvastatin | 353 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 328 | 84 |
| Lisinopril | Lisinopril | 294 | 82 |
| Donepezil Hcl | Donepezil Hcl | 279 | 39 |
| Potassium Chloride | Potassium Chloride | 258 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 257 | 64 |
| Carvedilol | Carvedilol | 255 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 249 | 82 |
| Levetiracetam | Levetiracetam | 246 | 42 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 242 | 121 |
| Trazodone Hcl | Trazodone Hcl | 241 | 51 |
| Glipizide | Glipizide | 239 | 51 |
| Memantine Hcl | Memantine Hcl | 225 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 217 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 214 | 90 |
| Hydrochlorothiazide | Hydrochlorothiazide | 213 | 62 |
| Pravastatin Sodium | Pravastatin Sodium | 211 | 47 |
| Lorazepam | Lorazepam | 202 | 48 |
| Allopurinol | Allopurinol | 194 | 65 |
| Hydralazine Hcl | Hydralazine Hcl | 191 | 66 |
| Divalproex Sodium | Divalproex Sodium | 180 | 26 |
| Finasteride | Finasteride | 168 | 33 |
| Atenolol | Atenolol | 162 | 38 |
| Alendronate Sodium | Alendronate Sodium | 159 | 42 |
| Prednisone | Prednisone | 159 | 75 |
| Ibuprofen | Ibuprofen | 150 | 67 |
| Januvia | Sitagliptin Phosphate | 143 | 21 |
| Latanoprost | Latanoprost | 140 | 29 |
| Mirtazapine | Mirtazapine | 137 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 132 | 77 |
| Amoxicillin | Amoxicillin | 131 | 97 |
| Fluticasone Propionate | Fluticasone Propionate | 131 | 59 |
| Baclofen | Baclofen | 130 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 130 | 98 |
| Famotidine | Famotidine | 128 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 123 | 24 |
| Spironolactone | Spironolactone | 123 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 119 | 25 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 116 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 31 |
| Xarelto | Rivaroxaban | 101 | 20 |
| Midodrine Hcl | Midodrine Hcl | 95 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 94 | 28 |
| Valsartan | Valsartan | 94 | 24 |
| Cephalexin | Cephalexin | 90 | 61 |
| Levofloxacin | Levofloxacin | 89 | 71 |
| Lactulose | Lactulose | 87 | 17 |
| Nitroglycerin | Nitroglycerin | 84 | 38 |
| Doxycycline Hyclate | Doxycycline Hyclate | 82 | 42 |
| Sertraline Hcl | Sertraline Hcl | 80 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 79 | 20 |
| Jardiance | Empagliflozin | 76 | 27 |
| Naproxen | Naproxen | 75 | 45 |
| Azithromycin | Azithromycin | 74 | 57 |
| Montelukast Sodium | Montelukast Sodium | 74 | 23 |
| Nystatin | Nystatin | 74 | 45 |
| Hydrocortisone | Hydrocortisone | 70 | 33 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 70 | 15 |
| Alprazolam | Alprazolam | 69 | 12 |
| Nifedipine Er | Nifedipine | 68 | 20 |
| Ozempic | Semaglutide | 68 | 17 |
| Rybelsus | Semaglutide | 68 | 22 |
| Meloxicam | Meloxicam | 67 | 33 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 64 | 43 |
| Glimepiride | Glimepiride | 64 | 25 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 64 | 23 |
| Bumetanide | Bumetanide | 61 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 34 |
| Meclizine Hcl | Meclizine Hcl | 59 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 58 | 53 |
| Digoxin | Digoxin | 57 | 13 |
| Promethazine Hcl | Promethazine Hcl | 57 | 14 |
| Methimazole | Methimazole | 56 | suppressed |
| Aripiprazole | Aripiprazole | 55 | suppressed |
| Sucralfate | Sucralfate | 55 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | suppressed |
| Entresto | Sacubitril/Valsartan | 54 | 13 |
| Risperidone | Risperidone | 54 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 53 | 12 |
| Olanzapine | Olanzapine | 53 | suppressed |
| Fenofibrate | Fenofibrate | 52 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 52 | 11 |
| Clonidine Hcl | Clonidine Hcl | 51 | 20 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Vascepa | Icosapent Ethyl | 50 | 14 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 49 | 27 |
| Buspirone Hcl | Buspirone Hcl | 48 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 47 | suppressed |
| Humulin R | Insulin Regular, Human | 47 | 11 |
| Tramadol Hcl | Tramadol Hcl | 47 | 25 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 47 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 28 |
| Ezetimibe | Ezetimibe | 43 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Glipizide Er | Glipizide | 43 | 11 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 41 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 40 | 15 |
| Lovastatin | Lovastatin | 40 | suppressed |
| Clozapine Odt | Clozapine | 39 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 39 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 39 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 12 |
| Brilinta | Ticagrelor | 36 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 36 | suppressed |
| Metolazone | Metolazone | 36 | 11 |
| Terazosin Hcl | Terazosin Hcl | 36 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Lacosamide | Lacosamide | 33 | suppressed |
| Metronidazole | Metronidazole | 33 | 29 |
| Avycaz | Ceftazidime/Avibactam | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Celecoxib | Celecoxib | 31 | 18 |
| Clobetasol Propionate | Clobetasol Propionate | 31 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 29 | suppressed |
| Dutasteride | Dutasteride | 29 | 12 |
| Novolin N | Insulin Nph Human Isophane | 29 | suppressed |
| Valproic Acid | Valproic Acid | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 28 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 28 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 27 | suppressed |
| Creon | Lipase/Protease/Amylase | 26 | suppressed |
| Erythromycin | Erythromycin Base | 26 | 22 |
| Farxiga | Dapagliflozin Propanediol | 26 | 11 |
| Insulin Aspart Flexpen | Insulin Aspart | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Colchicine | Colchicine | 24 | 13 |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 24 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 24 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 23 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 22 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 21 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 21 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Trulicity | Dulaglutide | 21 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 20 | suppressed |
| Acarbose | Acarbose | 18 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 18 | suppressed |
| Clotrimazole | Clotrimazole | 18 | 11 |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Nystop | Nystatin | 18 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 16 |
| Humalog | Insulin Lispro | 17 | suppressed |
| Novolin R | Insulin Regular, Human | 17 | suppressed |
| Novolog | Insulin Aspart | 17 | suppressed |
| Procto-Med Hc | Hydrocortisone | 17 | 11 |
| Clonidine | Clonidine | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Permethrin | Permethrin | 16 | 11 |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Tacrolimus | Tacrolimus | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Ertapenem | Ertapenem Sodium | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Insulin Aspart | Insulin Aspart | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Methadone Hcl | Methadone Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Trospium Chloride | Trospium Chloride | 14 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Klayesta | Nystatin | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 12 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 11 | suppressed |
| Restasis Multidose | Cyclosporine | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $639.53 · 28 records | Kowa Pharmaceuticals America, Inc. | Briviact, Cologuard Collection Kit, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, NUZYRA, Nayzilam, Ozempic, REXULTI, SHINGRIX, TRELEGY ELLIPTA, Vest Therapy Und, ZENPEP, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error